Power Of Proprietary Drug Names To Be Studied By US FDA
FDA is worried about drug names that could appear to overstate efficacy and impact consumer and healthcare provider perceptions of the product.
You may also be interested in...
Agency hasn't named the celebrity that will participate in the study on the impact that celebrity and non-celebrity endorsements have on consumer perceptions about Rx drugs.
US FDA's lead name reviewer laid out slew of reasons why the two names could be confused; her bosses agreed with the individual points, but felt that mitigation measures to avoid confusion were sufficient when considered holistically.
US FDA responds to comments on proposed study of product disclosures and study of amount and location of risk information.